Previous Close | 9.39 |
Open | 9.47 |
Bid | 9.33 x 0 |
Ask | 9.74 x 0 |
Day's Range | 9.45 - 9.54 |
52 Week Range | 6.37 - 15.91 |
Volume | |
Avg. Volume | 1,099,443 |
Market Cap | 6.747B |
Beta (5Y Monthly) | 0.50 |
PE Ratio (TTM) | 59.33 |
EPS (TTM) | 0.16 |
Earnings Date | May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jun 03, 2021 |
1y Target Est | N/A |
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").
The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi
MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.